With chemistry, manufacturing and controls (CMC) activities comprising as much as 15% of R&D spend, companies can ill-afford to make a mistake. And when you consider that 1 out of 10 first-cycle regulatory reviews are rejected due to CMC-related issues, millions of dollars are potentially at risk. Add both of these points to specific challenges in African markets and the challenges are exponentially greater.
Join Clarivate’s Life Sciences experts for a review of regulatory challenges in Sub-Saharan African (SSA) and how to overcome them. During the meeting, they’ll provide tips and insights on how to:
Position your drug for success and have greater confidence in your regulatory submissions.
1/10: https://jamanetwork.com/journals/jama/fullarticle/1817795
15%: 2018 CMR Factbook from Clarivate Analytics: Drawn from the 2018 R&D Investment Metrics Programme